Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial
| العنوان: | Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial |
|---|---|
| المؤلفون: | Areoo Samaei, Amir Ashraf-Ganjouei, Farzin Rezaei, Sayna Bagheri, Rosa Alikhani, Seiedeh Bentolhoda Mousavi, Kamyar Moradi, Shahin Akhondzadeh |
| المصدر: | International Journal of Neuropsychopharmacology |
| بيانات النشر: | Oxford University Press, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, AcademicSubjects/MED00415, Placebo-controlled study, resveratrol, Placebo, Regular Research Articles, Antioxidants, Extrapyramidal symptoms, Double-Blind Method, Internal medicine, Outcome Assessment, Health Care, medicine, Humans, Pharmacology (medical), Pharmacology, Risperidone, Positive and Negative Syndrome Scale, business.industry, AcademicSubjects/SCI01870, primary negative symptoms, clinical trial, Middle Aged, medicine.disease, Clinical trial, schizophrenia, Psychiatry and Mental health, Tolerability, Schizophrenia, Drug Therapy, Combination, Female, medicine.symptom, business, medicine.drug, Antipsychotic Agents |
| الوصف: | Background Patients with schizophrenia can generally manifest a broad variety of primary negative symptoms. The current study aimed to assess the efficacy and tolerability of resveratrol add-on therapy in the treatment of negative symptoms in patients with stable schizophrenia. Methods In a randomized, double-blind, and placebo-controlled setting, schizophrenia patients were assigned to receive either 200 mg/d resveratrol or matched placebo in addition to a stable dose of risperidone for 8 weeks. Patients were assessed using the positive and negative syndrome scale, the extrapyramidal symptom rating scale, and Hamilton Depression Rating Scale over the trial period. The primary outcome was considered as the change in positive and negative subscale score from baseline to week 8 between the treatment arms. Results A total 52 patients completed the trial (26 in each arm). Baseline characteristics of both groups were statistically similar (P > .05). Despite the statistically similar behavior of positive symptoms between the groups across time (Greenhouse-Geisser corrected: F = 1.76, df = 1.88, P = .180), the resveratrol group demonstrated greater improvement in negative, general psychopathology, and total scores (Greenhouse-Geisser corrected: F = 12.25, df = 2.04, P Conclusion Adding resveratrol to risperidone can exhibit remarkable efficacy and safety in terms of management of schizophrenia-related negative symptoms. |
| اللغة: | English |
| تدمد: | 1469-5111 1461-1457 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20187337e40c32d88077ffb88a5d43ad http://europepmc.org/articles/PMC7770519 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....20187337e40c32d88077ffb88a5d43ad |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14695111 14611457 |
|---|